Concepedia

Gary C. Starling

GC

43

Publications

2.6K

Citations

26

H-Index

1987

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Christchurch Hospital

Merck & Co., Inc., Rahway, NJ, USA (United States)

University of Washington

Gary C. Starling is an author at Bristol-Myers Squibb (United States) specializing in medicine, immunology, and cell biology.

ORCID

Top concepts

Publications per year

1987–2023

43

Publications

43

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

Shauna M. Collins, Courtney E. Bakan, Gina D. Swartzel et al. · Cancer Immunology Immunotherapy · 2013 · 291 citations · Full text

, , +6

Differential Induction of Apoptosis by Fas–Fas Ligand Interactions in Human Monocytes and Macrophages

Peter A. Kiener, Patricia M. Davis, Gary C. Starling et al. · The Journal of Experimental Medicine · 1997 · 244 citations · Full text

Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation

Peter A. Kiener, Patricia M. Davis, Bruce Rankin et al. · The Journal of Immunology · 1997 · 203 citations · Full text

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

Balaji Balasa, Rui Yun, Nicole A. Belmar et al. · Cancer Immunology Immunotherapy · 2014 · 152 citations · Full text

Activation of human peripheral blood dendritic cells induces the CD86 co‐stimulatory molecule

Alexander D. McLellan, Gary C. Starling, Lisa A. Williams et al. · European Journal of Immunology · 1995 · 134 citations

, , +15

Rows per page

1–5 of 43